WHO R&D Blueprint COVID-19
At present, there are no vaccines, no curative treatments and a strong need for more rapid diagnostic tests for COVID-19. Therefore, research is needed to accelerate timely, adequate, affordable and equitable access to these products. Switzerland supports WHO efforts to elaborate a research roadmap based on knowledge gaps for COVID-19 pandemic treatments, vaccines and related epidemiological studies, with a focus on low- and middle income countries.
Paese/Regione | Tema | Periodo | Budget |
---|---|---|---|
Mondo |
Sanità
Malattie infettive
Rafforzamento dei sistemi sanitari |
01.09.2020
- 31.08.2023 |
CHF 2’000’000
|
- Organizzazione mondiale della sanità
-
Settore in base alle categorie del Comitato di Aiuto allo sviluppo (DAC) dell'OCSE SALUTE
SALUTE
Sotto-Settore in base alle categorie del Comitato di Aiuto allo sviluppo (DAC) dell'OCSE Controllo delle malattie infettive
Politica sanitaria e gestione amministrativa
Tipo di aiuto Contributo al progetto e al programma
Numero del progetto 7F10584
Contesto |
With the announcement by WHO on 30.01.2020 that the novel coronavirus constituted a Public Health Emergency of International Concern, a Research and Development (R&D) program for COVID-19 was activated (“WHO R&D Blueprint”). On 11-12.02.2020, WHO convened a Global Research Summit where 500+ scientists identified critical research priorities. A coordinated Global Research and Innovation Roadmap was then developed. This proposal is aligned with the priorities of this Roadmap, with a focus on treatments, vaccines and related epidemiological studies. The research roadmap with its clear priority setting in research on diagnostics, therapies and vaccines against COVID-19 is essential for Switzerland which formally participates to the trials. This support is also complementary to Switzerland’s contribution to the Coalition for Epidemic Preparedness Innovations (CEPI). |
Obiettivi | Accelerate research for timely, adequate, affordable and equitable access to any innovation and medical countermeasures to those at risk of COVID-19, with a focus on LMICs. |
Gruppi target |
Researchers and clinicians in LMICs. The global research and development community for COVID-19. Key funders and implementing partners including GAVI, CEPI, Wellcome Trust. Manufacturers, regulators and procurement agencies (UNICEF, Global Fund, etc.). Patients and population at high risk for COVID-19. |
Effetti a medio termine |
· Therapeutics Solidarity Trial[1] have identified treatments that lead to a reduction in all-cause mortality and a reduction in the duration of hospital stay. · Vaccine Solidarity Trials have identified candidate vaccines for licensure and equitable access to those at highest risk. - Solidarity epidemiological studies have generated evidence on risk factors for transmission; impact of infection prevention and control measures in health care settings; incidence of infection, viral persistence on surfaces, etc. [1] The Solidarity Trial is an international clinical trial to help find an effective treatment for COVID-19, launched by WHO and partners. It is hoped that one or more of the treatments under trial will result in improving clinical outcomes in COVID-19 patients and save lives. |
Risultati |
Risultati principali attesi: · LMICs have participated in Solidarity trial · Collaborators in LMICs have participated - Collaborators in LMICs have joined Solidarity Risultati fasi precedenti: Not applicable. This is a new proposal. |
Direzione/Ufficio responsabile |
DSC |
Credito |
Cooperazione allo sviluppo |
Partner del progetto |
Partner contrattuale Organizzazione delle Nazioni Unite (ONU) Altri partner Governments, NGOs, private sector |
Coordinamento con altri progetti e attori | GAVI, COVAX AMC and COVAX Facility, CEPI, FIND |
Budget | Fase in corso Budget Svizzera CHF 2’000’000 Budget svizzero attualmente già speso CHF 2’000’000 |
Fasi del progetto |
Fase 1 01.09.2020 - 31.08.2023 (Completed) |